It is known from previous studies that Hox dysregulation in leukemia is usually concomitant with gain or loss of function mutations in upstream regulators, most commonly in Mixed Lineage Leukemia-1 (MLL-1) fusion proteins89,90, or loss of function Enhancer of Zeste Homolog 2 (EZH2) mutations91. This evidence concerns the gene KMT2A and leukemia.